Moderna cuts back on manufacturing; Lilly eyes Mounjaro supply boost; GSK’s shingles vaccine ‘unconstrained’

End­points News dug in­to this week’s earn­ings calls to gath­er bio­phar­ma man­u­fac­tur­ing up­dates. We found that Mod­er­na is cut­ting its man­u­fac­tur­ing ac­tiv­i­ties, while Am­gen pro­vid­ed up­dates on two fa­cil­i­ty builds.

Mod­er­na has start­ed down­siz­ing its man­u­fac­tur­ing in the third quar­ter as the Covid-19 pan­dem­ic shifts to an epi­dem­ic. The com­pa­ny’s man­u­fac­tur­ing foot­print was “built for a pan­dem­ic,” chief fi­nan­cial of­fi­cer James Mock said on an earn­ings call Thurs­day. Mod­er­na is un­der­go­ing “con­tin­u­ous im­prove­ment projects to dri­ve a re­duc­tion in cost of man­u­fac­tur­ing,” CEO Stéphane Ban­cel added, ac­cord­ing to an Al­phaSense tran­script.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.